Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.
CD39
CD73
COVID-19
Purinergic signaling
Targeted therapy
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
13
07
2023
accepted:
12
09
2023
medline:
4
12
2023
pubmed:
8
10
2023
entrez:
8
10
2023
Statut:
ppublish
Résumé
The pathogenesis of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), is complex and involves dysregulated immune responses, inflammation, and coagulopathy. Purinergic signaling, mediated by extracellular nucleotides and nucleosides, has emerged as a significant player in the pathogenesis of COVID-19. Extracellular adenosine triphosphate (ATP), released from damaged or infected cells, is a danger signal triggering immune responses. It activates immune cells, releasing pro-inflammatory cytokines, contributing to the cytokine storm observed in severe COVID-19 cases. ATP also promotes platelet activation and thrombus formation, contributing to the hypercoagulability seen in COVID-19 patients. On the other hand, adenosine, an immunosuppressive nucleoside, can impair anti-viral immune responses and promote tissue damage through its anti-inflammatory effects. Modulating purinergic receptors represents a promising therapeutic strategy for COVID-19. Understanding the role of purinergic signaling in COVID-19 pathogenesis and developing targeted therapeutic approaches can potentially improve patient outcomes. This review focuses on the part of purinergic signaling in COVID-19 pathogenesis and highlights potential therapeutic approaches targeting purinergic receptors.
Identifiants
pubmed: 37805959
doi: 10.1007/s10787-023-01344-4
pii: 10.1007/s10787-023-01344-4
doi:
Substances chimiques
Adenosine Triphosphate
8L70Q75FXE
Adenosine
K72T3FS567
Receptors, Purinergic
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3005-3020Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Abbasifard M, Khorramdelazad H (2020) The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. Life Sci 257:118097
pubmed: 32679148
pmcid: 7361088
doi: 10.1016/j.lfs.2020.118097
Ahmadi P, Hartjen P, Kohsar M, Kummer S, Schmiedel S, Bockmann J-H, Fathi A, Huber S, Haag F, Schulze zur Wiesch J (2020) Defining the CD39/CD73 axis in SARS-CoV-2 infection: the CD73-phenotype identifies polyfunctional cytotoxic lymphocytes. Cells 9(8): 1750
Ahmadi P, Hartjen P, Kohsar M, Kummer S, Schmiedel S, Bockmann JH, Fathi A, Huber S, Haag F, Schulze Zur Wiesch J (2020) Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes. Cells 9(8)
Aliter KF, Al-Horani RA (2021) Potential therapeutic benefits of dipyridamole in COVID-19 patients. Curr Pharm Des 27(6):866–875
pubmed: 33001004
pmcid: 7990686
doi: 10.2174/1381612826666201001125604
Allaoui A, Khawaja AA, Badad O, Naciri M, Lordkipanidzé M, Guessous F, Zaid Y (2021) Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 47(4):419–426
pubmed: 33851385
doi: 10.1055/s-0041-1726033
Allard B, Allard D, Buisseret L, Stagg J (2020) The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol 17(10):611–629
pubmed: 32514148
doi: 10.1038/s41571-020-0382-2
Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J (2019) Targeting the CD73-adenosine axis in immuno-oncology. Immunol Lett 205:31–39
pubmed: 29758241
doi: 10.1016/j.imlet.2018.05.001
Antonioli L, Pacher P, Vizi ES, Haskó G (2013) CD39 and CD73 in immunity and inflammation. Trends Mol Med 19(6):355–367
pubmed: 23601906
pmcid: 3674206
doi: 10.1016/j.molmed.2013.03.005
Ayan M, Kovelamudi S, Al-Hawwas M (2020) Subacute stent thrombosis in a patient with COVID-19 pneumonia. Proc (bayl Univ Med Cent) 34(1):175–177
pubmed: 33456191
Baconguis I, Hattori M, Gouaux E (2013) Unanticipated parallels in architecture and mechanism between ATP-gated P2X receptors and acid sensing ion channels. Curr Opin Struct Biol 23(2):277–284
pubmed: 23628284
pmcid: 3725955
doi: 10.1016/j.sbi.2013.04.005
Battastini AMO, Figueiró F, Leal DBR, Doleski PH, Schetinger MRC (2021) CD39 and CD73 as promising therapeutic targets: what could be the limitations? Front Pharmacol 12:633603
pubmed: 33815115
pmcid: 8014611
doi: 10.3389/fphar.2021.633603
Bergamin LS, Braganhol E, Zanin RF, Edelweiss MIA, Battastini AMO (2012) "Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview. Journal of Biomedicine and Biotechnology 2012.
Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 7(2):99–109
pubmed: 19148178
pmcid: 2910423
doi: 10.1038/nrmicro2070
Board A, Bihari D (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. JAMA 290:238–247
doi: 10.1001/jama.290.2.238
Borah P, Deka S, Mailavaram RP, Deb PK (2019) P1 receptor agonists/antagonists in clinical trials-potential drug candidates of the future. Curr Pharm Des 25(26):2792–2807
pubmed: 31333097
doi: 10.2174/1381612825666190716111245
Borges do Nascimento IJ, Cacic N, Abdulazeem HM, Von Groote TC, Jayarajah U, Weerasekara I, Esfahani MA, Civile VT A. Marusic and A. Jeroncic (2020) Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis J Clin Med 9(4): 941
Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell’Acqua ML (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood J Am Soc Hematol 110(4):1225–1232
Burnstock G (2000) P2X receptors in sensory neurones. Br J Anaesth 84(4):476–488
pubmed: 10823099
doi: 10.1093/oxfordjournals.bja.a013473
Burnstock G (2006) Purinergic signalling—an overview. Purinergic signalling in neuron–glia interactions: novartis foundation symposium 276, Wiley Online Library.
Burnstock G (2018) Purine and purinergic receptors. Brain Neurosci Adv 2:2398212818817494
pubmed: 32166165
pmcid: 7058212
doi: 10.1177/2398212818817494
Caillon A, Trimaille A, Favre J, Jesel L, Morel O, Kauffenstein G (2022) Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID-19-associated thrombopathy. J Thromb Haemost 20(1):17–31
pubmed: 34672094
pmcid: 8646423
doi: 10.1111/jth.15566
Campos-Contreras ADR, Díaz-Muñoz M, Vázquez-Cuevas FG (2020) Purinergic signaling in the hallmarks of cancer Cells 9(7)
Caracciolo M, Correale P, Mangano C, Foti G, Falcone C, Macheda S, Cuzzola M, Conte M, Falzea AC, Iuliano E (2021) Efficacy and effect of inhaled adenosine treatment in hospitalized COVID-19 patients. Front Immunol 12:613070
pubmed: 33815368
pmcid: 8012541
doi: 10.3389/fimmu.2021.613070
Cardoso AM (2020) COVID-19 and purinergic signaling: the need for investigation. Purinergic Signalling 16(3):451–452
pubmed: 32661586
pmcid: 7357433
doi: 10.1007/s11302-020-09713-2
Carotti V, Rigalli JP, van Asbeck-van der Wijst J, Hoenderop JG (2022) Interplay between purinergic signalling and extracellular vesicles in health and disease. Biochem Pharmacol 115192.
Cavaliere F, Donno C, D’Ambrosi N (2015) Purinergic signaling: a common pathway for neural and mesenchymal stem cell maintenance and differentiation. Front Cell Neurosci 9:211
pubmed: 26082684
pmcid: 4451364
doi: 10.3389/fncel.2015.00211
Chaves SP, Torres-Santos EC, Marques C, Figliuolo VR, Persechini PM, Coutinho-Silva R, Rossi-Bergmann B (2009) Modulation of P2X7 purinergic receptor in macrophages by Leishmania amazonensis and its role in parasite elimination. Microbes Infect 11(10–11):842–849
pubmed: 19439191
doi: 10.1016/j.micinf.2009.05.001
Choudhary R, Kaushik A, Sharma JB (2020) COVID-19 pandemic and stent thrombosis in a post percutaneous coronary intervention patient-a case report highlighting the selection of P2Y12 inhibitor. Cardiovasc Diagnosis Therapy 10(4):898
doi: 10.21037/cdt-20-485
Colgan SP, Eltzschig HK, Eckle T, Thompson LF (2006) Physiological roles for ecto-5’-nucleotidase (CD73). Purinergic Signal 2:351–360
pubmed: 18404475
pmcid: 2254482
doi: 10.1007/s11302-005-5302-5
Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, Junger WG (2008) Ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem 283(42):28480–28486
pubmed: 18713747
pmcid: 2568933
doi: 10.1074/jbc.M800039200
Corriden R, Insel PA (2010) Basal release of ATP: an autocrine-paracrine mechanism for cell regulation. Sci Signal 3(104): re1-re1.
Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116(2):205–219
pubmed: 14744432
doi: 10.1016/S0092-8674(04)00046-7
De Leve S, Wirsdörfer F, Jendrossek V (2019) Targeting the immunomodulatory CD73/adenosine system to improve the therapeutic gain of radiotherapy. Front Immunol 10:698
pubmed: 31024543
pmcid: 6460721
doi: 10.3389/fimmu.2019.00698
Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36(3):293–303
pubmed: 27321181
doi: 10.1038/onc.2016.206
Dorneles GP, Teixeira PC, da Silva IM, Schipper LL, Santana Filho PC, Rodrigues Junior LC, Bonorino C, Peres A, Fonseca SG, Monteiro MC (2022) Alterations in CD39/CD73 axis of T cells associated with COVID-19 severity. J Cell Physiol 237(8):3394–3407
pubmed: 35754396
pmcid: 9349448
doi: 10.1002/jcp.30805
dos Santos-Rodrigues A, Grañé-Boladeras N, Bicket A, Coe IR (2014) Nucleoside transporters in the purinome. Neurochem Int 73:229–237
pubmed: 24704797
doi: 10.1016/j.neuint.2014.03.014
Dou L, Chen Y-F, Cowan PJ, Chen X-P (2018) Extracellular ATP signaling and clinical relevance. Clin Immunol 188:67–73
pubmed: 29274390
doi: 10.1016/j.clim.2017.12.006
Erb L, Weisman GA (2012) Coupling of P2Y receptors to G proteins and other signaling pathways. Wiley Interdisciplinary Rev 1(6):789–803
Farnoosh G, Ghanei M, Khorramdelazad H, Alishiri G, Farahani AJ, Shahriary A, Zijoud SRH (2020) Are Iranian sulfur mustard gas-exposed survivors more vulnerable to SARS-CoV-2? Some similarity in their pathogenesis. Disaster Med Public Health Prep 14(6):826–832
pubmed: 32418550
doi: 10.1017/dmp.2020.156
Ferrari D, McNamee EN, Idzko M, Gambari R, Eltzschig HK (2016) Purinergic signaling during immune cell trafficking. Trends Immunol 37(6):399–411
pubmed: 27142306
doi: 10.1016/j.it.2016.04.004
Ferrari D, Rubini M, Burns JS (2022) The Potential of Purinergic Signaling to Fight Viruses including SARS-CoV-2. Front Immunol: 2663.
Fields RD, Stevens B (2000) ATP: an extracellular signaling molecule between neurons and glia. Trends Neurosci 23(12):625–633
pubmed: 11137153
doi: 10.1016/S0166-2236(00)01674-X
Fountain SJ (2023) Purinergic neurotransmission and nucleotide receptors. Elsevier, Primer on the Autonomic Nervous System, pp 93–97
Franciosi MLM, Lima MDM, Schetinger MRC, Cardoso AM (2021) Possible role of purinergic signaling in COVID-19. Mol Cell Biochem 476(8):2891–2898
pubmed: 33740184
pmcid: 7973800
doi: 10.1007/s11010-021-04130-4
Fredholm BB, Irenius E, Kull B, Schulte G (2001) Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61(4):443–448
pubmed: 11226378
doi: 10.1016/S0006-2952(00)00570-0
Frise MC, Gates RE, Curry NS, Danbury CM (2020) Successful use of argatroban to treat a critically Ill patient with coagulopathy and nephropathy secondary to COVID-19. TH Open 4(04):e400–e402
pubmed: 33336140
pmcid: 7738232
doi: 10.1055/s-0040-1721501
Furusato B, Rhim JS (2009) CXCR4 and cancer. Chemokine Receptors in Cancer: 31–45.
Gando S, Wada T (2021) Thromboplasminflammation in COVID-19 coagulopathy: three viewpoints for diagnostic and therapeutic strategies. Front Immunol: 2292.
García-Villalba J, Hurtado-Navarro L, Peñín-Franch A, Molina-López C, Martínez-Alarcón L, Angosto-Bazarra D, Baroja-Mazo A, Pelegrin P (2022) Soluble P2X7 receptor is elevated in the plasma of COVID-19 patients and correlates with disease severity. Front Immunol 13:894470
pubmed: 35663992
pmcid: 9161710
doi: 10.3389/fimmu.2022.894470
Geiger JD, Khan N, Murugan M, Boison D (2020) Possible role of adenosine in COVID-19 pathogenesis and therapeutic opportunities. Front Pharmacol 11:594487
pubmed: 33324223
pmcid: 7726428
doi: 10.3389/fphar.2020.594487
Gessi S, Varani K, Merighi S, Fogli E, Sacchetto V, Benini A, Leung E, Mac-Lennan S, Borea PA (2007) Adenosine and lymphocyte regulation. Purinergic Signalling 3:109–116
pubmed: 18404424
pmcid: 2096755
doi: 10.1007/s11302-006-9042-y
Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-Farsangi M, Azizi G, Yousefi M, Jadidi-Niaragh F (2019) CD73 as a potential opportunity for cancer immunotherapy. Expert Opin Ther Targets 23(2):127–142
pubmed: 30556751
doi: 10.1080/14728222.2019.1559829
Ghiringhelli F, Bruchard M, Chalmin F, Rébé C (2012) Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012
Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305(5684):626–629
pubmed: 15286356
doi: 10.1126/science.1099320
Gupta N, Praharaj I, Bhatnagar T, Thangaraj JWV, Giri S, Chauhan H, Kulkarni S, Murhekar M, Singh S, Gangakhedkar RR (2020) Severe acute respiratory illness surveillance for coronavirus disease 2019, India, 2020. Indian J Med Res 151(2–3):236
pubmed: 32362647
pmcid: 7357403
Haas CB, Lovászi M, Braganhol E, Pacher P, Haskó G (2021) Ectonucleotidases in inflammation, immunity, and cancer. J Immunol 206(9):1983–1990
pubmed: 33879578
doi: 10.4049/jimmunol.2001342
Halpin-Veszeleiova K, Hatfield SM (2022) Therapeutic targeting of Hypoxia-A2-adenosinergic pathway in COVID-19 patients. Physiology 37(1):46–52
pubmed: 34486395
doi: 10.1152/physiol.00010.2021
Hashemi A, Madhavan MV, Bikdeli B (2020) Pharmacotherapy for prevention and management of thrombosis in COVID-19. Seminars in thrombosis and hemostasis, Thieme Medical Publishers.
Honda S, Sasaki Y, Ohsawa K, Imai Y, Nakamura Y, Inoue K, Kohsaka S (2001) Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J Neurosci 21(6):1975–1982
pubmed: 11245682
pmcid: 6762617
doi: 10.1523/JNEUROSCI.21-06-01975.2001
Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu S-G, Huang C (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6(1):162
pubmed: 33907179
pmcid: 8079716
doi: 10.1038/s41392-021-00553-z
Jamwal S, Mittal A, Kumar P, Alhayani DM, Al-Aboudi A (2019) Therapeutic potential of agonists and antagonists of A1, A2a, A2b and A3 adenosine receptors. Curr Pharm Des 25(26):2892–2905
pubmed: 31333104
doi: 10.2174/1381612825666190716112319
Jeffrey JL, Lawson KV, Powers JP (2020a) Targeting metabolism of extracellular nucleotides via Inhibition of ectonucleotidases CD73 and CD39. J Med Chem 63(22):13444–13465
pubmed: 32786396
doi: 10.1021/acs.jmedchem.0c01044
Jiang X, Wang X (2000) Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J Biol Chem 275(40):31199–31203
pubmed: 10940292
doi: 10.1074/jbc.C000405200
Kadenbach B, Arnold S, Lee I, Hüttemann M (2004) The possible role of cytochrome c oxidase in stress-induced apoptosis and degenerative diseases. Biochimica et Biophysica Acta (BBA)-Bioenergetics 1655: 400–408.
Kanthi Y, Knight JS, Zuo Y, Pinsky DJ (2020) New (re) purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm. JCI insight 5(14).
Kepp O, Loos F, Liu P, Kroemer G (2017) Extracellular nucleosides and nucleotides as immunomodulators. Immunol Rev 280(1):83–92
pubmed: 29027229
doi: 10.1111/imr.12571
Khorramdelazad H, Kazemi MH, Najafi A, Keykhaee M, Emameh RZ, Falak R (2021) Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection. Microb Pathog 152:104554
pubmed: 33157216
doi: 10.1016/j.micpath.2020.104554
Kumar D, Kaimaparambil V, Chandralekha S, Lalchandani J (2022) Oral rivaroxaban in the prophylaxis of COVID-19 induced coagulopathy. J Assoc Physicians India 70(2):11–12
pubmed: 37355977
Ledderose C, Bao Y, Kondo Y, Fakhari M, Slubowski C, Zhang J, Junger WG (2016) Purinergic signaling and the immune response in sepsis: a review. Clin Ther 38(5):1054–1065
pubmed: 27156007
pmcid: 4875817
doi: 10.1016/j.clinthera.2016.04.002
Leite-Aguiar R, Alves VS, Savio LEB, Coutinho-Silva R (2021) Targeting purinergic signaling in the dynamics of disease progression in sepsis. Front Pharmacol 11:626484
pubmed: 33519492
pmcid: 7840482
doi: 10.3389/fphar.2020.626484
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC (2022) Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 36(12):1689–1696
pubmed: 35848570
doi: 10.1097/QAD.0000000000003314
Li S, Li X, Guo H, Liu S, Huang H, Liu N, Yang C, Tang P, Liu J (2013) Intracellular ATP concentration contributes to the cytotoxic and cytoprotective effects of adenosine. PLoS ONE 8(10):e76731
pubmed: 24098558
pmcid: 3789704
doi: 10.1371/journal.pone.0076731
Linnemann C, Schildberg FA, Schurich A, Diehl L, Hegenbarth SI, Endl E, Lacher S, Müller CE, Frey J, Simeoni L (2009) Adenosine regulates CD8 T‐cell priming by inhibition of membrane‐proximal T‐cell receptor signalling. Immunology 128(1pt2): e728-e737
Mahmood A, Iqbal J (2022) Purinergic receptors modulators: an emerging pharmacological tool for disease management. Med Res Rev 42(4):1661–1703
pubmed: 35561109
doi: 10.1002/med.21888
Mazzeffi M, Chow JH, Amoroso A, Tanaka K (2020) Revisiting the protein C pathway: an opportunity for adjunctive intervention in COVID-19? Anesthesia and Analgesia
Mazzone SB, Satia I, McGarvey L, Song W-J, Chung KF (2022) Chronic cough and cough hypersensitivity: from mechanistic insights to novel antitussives. Lancet Respir Med 10(12):1113–1115
pubmed: 36372083
doi: 10.1016/S2213-2600(22)00404-0
Miller RA, Guru P, Bauer P, Robles J, Tomaszewski C, Overcash JS, Waters M, Cameron M, Olalla Sierra J, Mashhedi H (2021) Clinical results with a B cell activating Anti-CD73 antibody for the immunotherapy of COVID-19. MedRxiv: 2021.2009. 2013.21263406
Moesta AK, Li X-Y, Smyth MJ (2020) Targeting CD39 in cancer. Nat Rev Immunol 20(12):739–755
pubmed: 32728220
doi: 10.1038/s41577-020-0376-4
Morello S, Caiazzo E, Turiello R, Cicala C (2021) Thrombo-Inflammation: A Focus on NTPDase1/CD39. Cells 10(9)
Morello S, Caiazzo E, Turiello R, Cicala C (2021b) Thrombo-inflammation: a focus on NTPDase1/CD39. Cells 10(9):2223
pubmed: 34571872
pmcid: 8469976
doi: 10.3390/cells10092223
Nadeali Z, Mohammad-Rezaei F, Aria H, Nikpour P (2022a) Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19. Life Sci 297:120482
pubmed: 35288174
pmcid: 8915746
doi: 10.1016/j.lfs.2022.120482
Nakhaee H, Zangiabadian M, Bayati R, Rahmanian M, Ghaffari Jolfayi A, Rakhshanderou S (2022) The effect of antidepressants on the severity of COVID-19 in hospitalized patients: a systematic review and meta-analysis. PLoS ONE 17(10):e0267423
pubmed: 36201406
pmcid: 9536564
doi: 10.1371/journal.pone.0267423
Neo SY, Yang Y, Record J, Ma R, Chen X, Chen Z, Tobin NP, Blake E, Seitz C, Thomas R (2020) CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Investig 130(3):1185–1198
pubmed: 31770109
pmcid: 7269592
doi: 10.1172/JCI128895
Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N (2013) Crosstalk between apoptosis, necrosis and autophagy. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1833(12): 3448–3459.
North RA (2016) P2X receptors. PhilosophTrans R Soc b 371(1700):20150427
doi: 10.1098/rstb.2015.0427
Opdebeeck B, Orriss IR, Neven E, D’Haese PC, Verhulst A (2020) Extracellular nucleotides regulate arterial calcification by activating both independent and dependent purinergic receptor signaling pathways. Int J Mol Sci 21(20):7636
pubmed: 33076470
pmcid: 7589647
doi: 10.3390/ijms21207636
Paoletti A, Raza SQ, Voisin L, Law F, da Fonseca JP, Caillet M, Kroemer G, Perfettini J-L (2012) Multifaceted roles of purinergic receptors in viral infection. Microbes Infect 14(14):1278–1283
pubmed: 22683717
doi: 10.1016/j.micinf.2012.05.010
Passos DF, Schetinger MRC, Leal DB (2015) Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: from viral entry to therapy. World J Virol 4(3):285
pubmed: 26279989
pmcid: 4534819
doi: 10.5501/wjv.v4.i3.285
Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Dejou C, Jecko D, Becquart O (2019) Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 27(8): 2411–2425. e2419
Rabadi MM, Lee HT (2015) Adenosine receptors and renal ischaemia reperfusion injury. Acta Physiol 213(1):222–231
doi: 10.1111/apha.12402
Rabie AM (2022) Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication. ACS Omega 7(3):2960–2969
pubmed: 35071937
pmcid: 8767658
doi: 10.1021/acsomega.1c05998
Ranjbar M, Rahimi A, Baghernejadan Z, Ghorbani A, Khorramdelazad H (2022) Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible treatments: all options on the Table. Int Immunopharmacol 113:109325
pubmed: 36252475
pmcid: 9561120
doi: 10.1016/j.intimp.2022.109325
Reichert KP, Castro MFV, Assmann CE, Bottari NB, Miron VV, Cardoso A, Stefanello N, Morsch VMM, Schetinger MRC (2021) Diabetes and hypertension: pivotal involvement of purinergic signaling. Biomed Pharmacother 137:111273
pubmed: 33524787
pmcid: 7846467
doi: 10.1016/j.biopha.2021.111273
Ring S, Pushkarevskaya A, Schild H, Probst HC, Jendrossek V, Wirsdörfer F, Ledent C, Robson SC, Enk AH, Mahnke K (2015) Regulatory T cell–derived adenosine induces dendritic cell migration through the Epac-Rap1 pathway. J Immunol 194(8):3735–3744
pubmed: 25780038
doi: 10.4049/jimmunol.1401434
Rossato M, Favaretto F, Granzotto M, Crescenzi M, Boscaro A, Di Vincenzo A, Capone F, Dalla Nora E, Zabeo E, Vettor R (2022) Molecular and pharmacological evidence for the expression of multiple functional P2 purinergic receptors in human adipocytes. Molecules 27(6):1913
pubmed: 35335277
pmcid: 8954896
doi: 10.3390/molecules27061913
Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, Ricordi C, Westendorf AM, Grassi F (2011) ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 4(162): ra12–ra12
Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli M, Verderio C, Buer J, Scanziani E, Grassi F (2008) Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal 1(39): ra6-ra6
Shahbaz S, Xu L, Sligl W, Osman M, Bozorgmehr N, Mashhouri S, Redmond D, Perez Rosero E, Walker J, Elahi S (2021a) The quality of SARS-CoV-2-specific t cell functions differs in patients with mild/moderate versus severe disease, and t cells expressing coinhibitory receptors are highly activated. J Immunol 207(4):1099–1111
pubmed: 34312258
doi: 10.4049/jimmunol.2100446
Shahbaz S, Xu L, Sligl W, Osman M, Bozorgmehr N, Mashhouri S, Redmond D, Perez Rosero E, Walker J, Elahi S (2021b) The quality of SARS-CoV-2–specific T cell functions differs in patients with mild/moderate versus severe disease, and T cells expressing coinhibitory receptors are highly activated. J Immunol 207(4):1099–1111
pubmed: 34312258
doi: 10.4049/jimmunol.2100446
Shi H, Dai H, Sun Q, Wang S, Chen Y (2023) CD73, a significant protein in liver diseases. Front Med 10
Shivshankar P, Karmouty-Quintana H, Mills T, Doursout M-F, Wang Y, Czopik AK, Evans SE, Eltzschig HK, Yuan X (2022) SARS-CoV-2 infection: host response, immunity, and therapeutic targets. Inflammation 45(4):1430–1449
pubmed: 35320469
doi: 10.1007/s10753-022-01656-7
Simões JLB, Galvan ACL, da Silva ELM, Ignácio ZM, Bagatini MD (2022) Therapeutic potential of the purinergic system in major depressive disorder associated with COVID-19. Cell Mol Neurobiol: 1–17.
Sriram K, Insel PA (2020) Proteinase-activated receptor 1: a target for repurposing in the treatment of COVID-19? Br J Pharmacol 177(21):4971–4974
pubmed: 32639031
pmcid: 7361899
doi: 10.1111/bph.15194
Sriram K, Insel PA (2021) Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Physiol Rev 101(2):545–567
pubmed: 33124941
doi: 10.1152/physrev.00035.2020
Sun C, Jiao T, Merkus D, Duncker DJ, Mustafa SJ, Zhou Z (2019) Activation of adenosine A2A but not A2B receptors is involved in uridine adenosine tetraphosphate-induced porcine coronary smooth muscle relaxation. J Pharmacol Sci 141(1):64–69
pubmed: 31640919
pmcid: 7418061
doi: 10.1016/j.jphs.2019.09.006
Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Müller CE, Murakami T, Robson SC (2010) CD39/ENTPD1 expression by CD4+ Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139(3):1030–1040
pubmed: 20546740
doi: 10.1053/j.gastro.2010.05.007
Sundström P, Stenstad H, Langenes V, Ahlmanner F, Theander L, Ndah TG, Fredin K, Börjesson L, Gustavsson B, Bastid J (2016) Regulatory T cells from colon cancer patients inhibit effector T-cell migration through an adenosine-dependent mechanismtreg mediated inhibition of T-cell migration in cancer patients. Cancer Immunol Res 4(3):183–193
pubmed: 26787824
doi: 10.1158/2326-6066.CIR-15-0050
Surprenant A, Buell G, North RA (1995) P2X receptors bring new structure to ligand-gated ion channels. Trends Neurosci 18(5):224–229
pubmed: 7541920
doi: 10.1016/0166-2236(95)93907-F
Takenaka MC, Robson S, Quintana FJ (2016) Regulation of the T cell response by CD39. Trends Immunol 37(7):427–439
pubmed: 27236363
pmcid: 5215082
doi: 10.1016/j.it.2016.04.009
Tardif V, Muir R, Cubas R, Chakhtoura M, Wilkinson P, Metcalf T, Herro R, Haddad EK (2019) Adenosine deaminase-1 delineates human follicular helper T cell function and is altered with HIV. Nat Commun 10(1):823
pubmed: 30778076
pmcid: 6379489
doi: 10.1038/s41467-019-08801-1
Tokano M, Takagi R, Kawano M, Maesaki S, Tarumoto N, Matsushita S (2022) Signaling via dopamine and adenosine receptors modulate viral peptide-specific and T-cell IL-8 response in COVID-19. Immunological Medicine 45(3):162–167
pubmed: 35623041
doi: 10.1080/25785826.2022.2079369
Toro-Huamanchumo CJ, Benites-Meza JK, Mamani-García CS, Bustamante-Paytan D, Gracia-Ramos AE, Diaz-Vélez C, Barboza JJ (2022) Efficacy of colchicine in the treatment of COVID-19 patients: a systematic review and meta-analysis. J Clin Med 11(9):2615
pubmed: 35566737
pmcid: 9105993
doi: 10.3390/jcm11092615
Verma A, Ramayya T, Upadhyaya A, Valenta I, Lyons M, Marschall J, Dehdashti F, Gropler RJ, Woodard PK, Schindler TH (2022) Post COVID-19 syndrome with impairment of flow-mediated epicardial vasodilation and flow reserve. Eur J Clin Invest 52(12):e13871
pubmed: 36083297
doi: 10.1111/eci.13871
Vijayan D, Young A, Teng MW, Smyth MJ (2017) Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 17(12):709–724
pubmed: 29059149
doi: 10.1038/nrc.2017.86
Vultaggio-Poma V, Falzoni S, Salvi G, Giuliani AL, Di Virgilio F (2022) Signalling by extracellular nucleotides in health and disease. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research: 119237.
Vultaggio-Poma V, Sarti AC, Di Virgilio F (2020) Extracellular ATP: a feasible target for cancer therapy. Cells 9(11):2496
pubmed: 33212982
pmcid: 7698494
doi: 10.3390/cells9112496
Wang X, Chen D (2018) Purinergic regulation of neutrophil function. Front Immunol 9:399
pubmed: 29545806
pmcid: 5837999
doi: 10.3389/fimmu.2018.00399
Wernly B, Erlinge D, Pernow J, Zhou Z (2021) Ticagrelor: a cardiometabolic drug targeting erythrocyte-mediated purinergic signaling? Am J Physiol-Heart Circ Physiol 320(1):H90–H94
pubmed: 33095055
doi: 10.1152/ajpheart.00570.2020
Woehrle T, Yip L, Elkhal A, Sumi Y, Chen Y, Yao Y, Insel PA, Junger WG (2010) Pannexin-1 hemichannel–mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood J Am Soc Hematol 116(18):3475–3484
Woods LT, Forti KM, Shanbhag VC, Camden JM, Weisman GA (2021) P2Y receptors for extracellular nucleotides: contributions to cancer progression and therapeutic implications. Biochem Pharmacol 187:114406
pubmed: 33412103
pmcid: 8096679
doi: 10.1016/j.bcp.2021.114406
Xia C, Yin S, To KK, Fu L (2023) CD39/CD73/A2AR pathway and cancer immunotherapy. Mol Cancer 22(1):1–17
doi: 10.1186/s12943-023-01733-x
Yegutkin GG (2014) Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities. Crit Rev Biochem Mol Biol 49(6):473–497
pubmed: 25418535
doi: 10.3109/10409238.2014.953627
Yegutkin GG, Boison D (2022) ATP and adenosine metabolism in cancer: exploitation for therapeutic gain. Pharmacol Rev 74(3):797–822
pubmed: 35738682
doi: 10.1124/pharmrev.121.000528
Yoshioka K, Saitoh O, Nakata H (2001) Heteromeric association creates a P2Y-like adenosine receptor. Proc Natl Acad Sci 98(13):7617–7622
pubmed: 11390975
pmcid: 34717
doi: 10.1073/pnas.121587098
Zarei M, Sahebi Vaighan N, Ziai SA (2021a) Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19. Immunopharmacol Immunotoxicol 43(6):633–643
pubmed: 34647511
doi: 10.1080/08923973.2021.1988102
Zeng J, Ning Z, Wang Y, Xiong H (2020) Implications of CD39 in immune-related diseases. Int Immunopharmacol 89:107055
pubmed: 33045579
doi: 10.1016/j.intimp.2020.107055
Zhong T, Huang Z, Pang X, Chen N, Kwek K, Wynne C, Konpa A, Jin X, Xia Y, Wang MZ (2020) 476 AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19, BMJ Specialist Journals.
Zimmermann H (2016) Extracellular ATP and other nucleotides—ubiquitous triggers of intercellular messenger release. Purinergic Signalling 12(1):25–57
pubmed: 26545760
doi: 10.1007/s11302-015-9483-2